Bolt Biotherapeutics (NASDAQ:BOLT) Major Shareholder Acquires $319,000.00 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) major shareholder Coastlands Capital Lp purchased 50,000 shares of the firm’s stock in a transaction on Monday, November 9th. The shares were purchased at an average price of $6.38 per share, for a total transaction of $319,000.00. Following the completion of the purchase, the insider directly owned 462,416 shares of the company’s stock, valued at $2,950,214.08. This represents a 12.12% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bolt Biotherapeutics Trading Down 5.6%

BOLT opened at $5.91 on Friday. Bolt Biotherapeutics, Inc. has a 52 week low of $3.10 and a 52 week high of $7.78. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 1.47. The business has a fifty day simple moving average of $4.58 and a 200-day simple moving average of $4.52. The firm has a market cap of $11.38 million, a P/E ratio of -0.36 and a beta of 0.85.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($2.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.68) by $1.43. Bolt Biotherapeutics had a negative return on equity of 126.23% and a negative net margin of 611.47%. The firm had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.45 million. On average, equities analysts expect that Bolt Biotherapeutics, Inc. will post -11.10 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $14.50.

Institutional Investors Weigh In On Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. Renaissance Technologies LLC boosted its holdings in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 40.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 77,225 shares of the company’s stock after buying an additional 22,200 shares during the quarter. Renaissance Technologies LLC owned 4.02% of Bolt Biotherapeutics worth $312,000 as of its most recent SEC filing. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.